Sample Healthcare Paper on Alzheimer’s disease

Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive syndrome that affects the human brain and is mainly characterized by weakened memory and disorder in the human thinking capacity. The disease is commonly associated with the elderly population above the age of 65. Alzheimer’s malady is a form of dementia, which is a medical condition that affects the brain. In the United States, for instance, approximately 6.8 million people are affected by dementia and out of this population; 5.3 million have been diagnosed with the condition (DeFina et al. 1).As many individuals continue to age, the figures are anticipated to increase. AD condition has become a public health concern, mainly impacting individuals, families and healthcare resources.

AD diagnosis is commonly referred to as “diagnosis by exclusion,” which implies that it does not have a specific test. However, the common early stage symptom that is associated with the condition is short-term memory loss, for instance, one forgetting to turn off the cooker or not taking medications as prescribed (Weintraub et al. 2). As the condition progresses and approaches its final stages, the affected individuals become confused and dazed. At that point, their health status sternly worsens, leading to the development of pneumonia and other illnesses that may lead to loss of life. The primary symptom of an AD is memory loss. Moreover, there are four basic disorders among individuals affected by the condition: agitation, depression, psychosis, and anxiety. Most of the affected population does not die from an AD, but other health-related conditions. An individual can live with the state for about 6 to 8 years, though in some instances it can be present without noticeable symptoms, which can last for 2 to 20 years. The early stage of the disease is also gradual and painful to be detected.

Alzheimer’s disease is caused by several factors besides it being genetic. An individual associated with a family affected by the disease possesses an increased likelihood of being diagnosed with the condition. The ad is also caused by several conditions of the brain, for instance, a mutation of a particular gene is one state that is common in the patients’ brains. Some proteins are also found in the brain, which is associated with the condition. Alzheimer’s can be prevented through certain measures since it is a genetic condition besides its prevalence being determined on how an individual’s genetic factor reacts to the environment. Initially, several people believed that drinking out of aluminum products was a common cause of Alzheimer’s, an assumption that has been proven wrong. Alzheimer’s disease is mainly as a result of the increase in the production of a particular protein, beta-amyloid, that kills a nerve cell (Jack et al. 259).

Although there is no specific remedy for Alzheimer’s disease, several treatments protract an individual’s cognizance and memory. AD patient medications are applied in the early stages to abate memory loss in patients (Casey 208). Among the advisable medicines that have had a positive impact is tacrine. The drug helps in increasing the acetylcholine that is significant in improving an individual’s memory. Moreover, AD patients are also prescribed anti-depressants and anti-anxiety remedies that help in controlling their moods. Such medications are commonly referred to as cholinesterase inhibitors and have been approved for managing Alzheimer’s disease. Although the drugs have been useful in managing the condition, the inheritances of the affected population ascertain that each case is different, and the signs and symptoms of Alzheimer’s differ for each patient. Nonetheless, the drugs are most effective when introduced in the earliest phases of the syndrome. When individuals are added to these drugs, it is advisable that medical practitioners do not recommend more than one since there are several side effects. Individuals affected by AD Alzheimer should not be subjected to take them medications throughout their lives but need to be carefully monitored anytime they stop using them.

 

Works Cited

Casey, David A., Demetra Antimisiaris, and James O’Brien. “Drugs for Alzheimer’s disease: are they effective?” Pharmacy and Therapeutics 35.4 (2010): 208.

DeFina, Philip A., Rosemarie S. Scolaro, Megan G., Jonathan D. Lichtenstein and Jonathan Fellus. “Alzheimer’s disease clinical and research update for healthcare practitioners.” Journal of aging research 2013 (2013).

Jack, Clifford R., Marlyn S. Albert, David S, Knopman, Guy N, Mackhann, Reisa A. Sperling, Mario C. Carillo, Bill Thies and Creighton H. Phelps. “Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.” Alzheimer’s & Dementia 7.3 (2011): 257-262.

Weintraub, Sandra, Alissa H. Wicklund, and David P. Salmon. “The neuropsychological profile of Alzheimer disease.” Cold Spring Harbor perspectives in medicine 2.4 (2012): a006171.